Factor IX mutants with enhanced catalytic activity

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 10, 2009, Pages 1656-1662

  Hartmann, R ^a   Dockal, M ^a   Kammlander, W ^a   Panholzer, E ^a   Nicolaes, G A ^b   Fiedler, C ^a   Rosing, J ^b   Scheiflinger, F ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Factor IX; Factor VIII; Increased catalytic efficiency

Indexed keywords

BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; RECOMBINANT BLOOD CLOTTING FACTOR 9; THROMBIN;

AMINO ACID SUBSTITUTION; ARTICLE; BLOOD CLOTTING; CATALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; MUTATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN PROCESSING;

AMINO ACID SUBSTITUTION; CATALYSIS; CATALYTIC DOMAIN; CHROMOGENIC COMPOUNDS; ENZYME PRECURSORS; FACTOR IX; FACTOR VIII; FACTOR X; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; OLIGOPEPTIDES; PARTIAL THROMBOPLASTIN TIME; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN;

EID: 70350028359     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03560.x     Document Type: Article

References (14)

1. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981, 256:3433-42.
2. Brandstetter H, Bauer M, Huber R, Lollar P, Bode W. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci USA 1995, 92:9796-800.
3. Padmanabhan K, Padmanabhan KP, Tulinsky A, Park CH, Bode W, Huber R, Blankenship DT, Cardin AD, Kisiel W. Structure of human des(1-45) factor Xa at 2.2 A resolution. J Mol Biol 1993, 232:947-66.
4. Brandstetter H, Kuhne A, Bode W, Huber R, von der Saal W, Wirthensohn K, Engh RA. X-ray structure of active site-inhibited clotting factor Xa. Implications for drug design and substrate recognition. J Biol Chem 1996, 271:29988-92.
5. Hopfner KP, Lang A, Karcher A, Sichler K, Kopetzki E, Brandstetter H, Huber R, Bode W, Engh RA. Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding. Structure 1999, 7:989-96.
6. Kolkman JA, Mertens K. Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII. Biochemistry 2000, 39:7398-405.
7. Sarkar G, Koeberl DD, Sommer SS. Direct sequencing of the activation peptide and the catalytic domain of the factor IX gene in six species. Genomics 1990, 6:133-43.
8. Hedstrom L, Szilagyi L, Rutter WJ. Converting trypsin to chymotrypsin: the role of surface loops. Science 1992, 255:1249-53.
9. Hedstrom L. Trypsin: a case study in the structural determinants of enzyme specificity. Biol Chem 1996, 377:465-70.
10. Herlitschka SE, Schlokat U, Falkner FG, Dorner F. High expression of a B-domain deleted factor VIII gene in a human hepatic cell line. J Biotechnol 1998, 61:165-73.
11. Harrison S, Adamson S, Bonam D, Brodeur S, Charlebois T, Clancy B, Rostigan R, Drapeau D, Hamilton M, Hanley K, Kelley B, Knight A, Leonard M, McCarthy M, Oakes P, Sterl K, Switzer M, Walsh R, Foster W. The manufacturing process for recombinant factor IX. Semin Hematol 1998, 35:4-10.
12. Fischer B, Mitterer A, Dorner F. Purification of recombinant human coagulation factors II and IX and protein S expressed in recombinant Vaccinia virus-infected Vero cells. J Biotechnol 1995, 38:129-36.
13. Turecek PL, Gritsch H, Richter G, Auer W, Pichler L, Schwarz HP. Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost 1997, 77:591-9.
14. Sichler K, Kopetzki E, Huber R, Bode W, Hopfner KP, Brandstetter H. Physiological fIXa activation involves a cooperative conformational rearrangement of the 99-loop. J Biol Chem 2003, 278:4121-6.